Search

Your search keyword '"Bruck Heike"' showing total 167 results
Start Over Author "Bruck Heike"
167 results on '"Bruck Heike"'

1. Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia

Author

Kratochvil David, Amann Kerstin, Bruck Heike, and Büttner Maike

Subjects
Waldenström’s macroglobulinemia, MPGN, Hyaline thrombi, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Abstract Background Lymphoproliferative disorders causing paraproteinemia can be associated with various kidney injuries including the deposition of monoclonal immunoglobulins (Ig). A known glomerular manifestation of Waldenström’s macroglobulinemia is characterized by prominent intracapillary hyaline thrombi and lack of conspicuous glomerular proliferation. The present case was special in 2 aspects: 1. the diagnosis of glomerulonephritis was unexpected before renal biopsy, 2. the prominent glomerular proliferation paired with large intracapillary hyaline thrombi is uncommon in Waldenström’s macroglobulinemia-associated glomerulonephritis. Case presentation A 73-year-old Caucasian woman with a long-standing history of rheumatoid arthritis and Waldenström’s macroglobulinemia was admitted for acute renal failure (ARF), which initially was presumed to be the consequence of extrarenal causes. Proteinuria and hematuria were only mild. In renal core biopsy, a membranoproliferative glomerulonephritis (MPGN) and prominent intracapillary hyaline monoclonal IgM thrombi were found in addition to acute tubular necrosis. Of note, the patient’s history was positive for purpuric skin changes, suspicious for cryoglobulinemia. However, serological tests for cryoglobulins were repeatedly negative. The ARF resolved before the start of immunomodulatory therapy for Waldenström’s macroglobulinemia. Conclusion The presence of MPGN with prominent hyaline thrombi in the context of Waldenström’s macroglobulinemia is uncommon and can be oligosymptomatic. We discuss this case in the context of previous literature and classifications suggested for monoclonal Ig-related renal pathologies.

Published
2012
Full Text
View/download PDF

2. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

Author

Özcan, Fedai, Markau, Silke, Girndt, Matthias, Felten, Helmut, Hausberg, Martin, Brand, Marcus, Gerth, Jens, Bommer, Martin, Zschiedrich, Stefan, Schneider, Johanna, Elitok, Saban, Gawlik, Alexander, Schwenger, Vedat, Roeder, Maximilian, Radermacher, Jörg, Morgner, Anke, Herbst, Regina, von Auer, Charis, Völker, Linus A., Kaufeld, Jessica, Balduin, Gesa, Merkel, Lena, Kühne, Lucas, Eichenauer, Dennis A., Osterholt, Thomas, Hägele, Holger, Kann, Martin, Grundmann, Franziska, Kolbrink, Benedikt, Schulte, Kevin, Gäckler, Anja, Kribben, Andreas, Boss, Kristina, Potthoff, Sebastian A., Rump, Lars C., Schmidt, Tilman, Mühlfeld, Anja S., Schulmann, Karsten, Hermann, Matthias, Gaedeke, Jens, Sauerland, Kristin, Bramstedt, Jörn, Hinkel, Ulrich P., Miesbach, Wolfgang, Bauer, Frederic, Westhoff, Timm H., Bruck, Heike, Buxhofer-Ausch, Veronika, Müller, Tobias J., Wendt, Ralph, Harth, Ana, Schreiber, Adrian, Seelow, Evelyn, Tölle, Markus, Gohlisch, Christopher, Bieringer, Markus, Geuther, Gesa, Jabs, Wolfram J., Fischereder, Michael, von Bergwelt-Baildon, Anke, Schönermarck, Ulf, Knoebl, Paul, Menne, Jan, and Brinkkoetter, Paul T.

Published
2023
Full Text
View/download PDF

3. Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation

Author

Orth-Alampour, Setareh, Gayrard, Nathalie, Salem, Silvia, Bhargava, Shruti, Jankowski, Vera, Jover, Bernard, Notarnicola, Cécile, Noels, Heidi, van der Vorst, Emiel P. C., Kuppe, Christoph, Wolf, Michael, Goettsch, Claudia, Theelen, Wendy, Bruck, Heike, Fliser, Danilo, Loscalzo, Joseph, Wu, Zhuojun, Marx, Nikolaus, Zidek, Walter, Argilés, Àngel, and Jankowski, Joachim

Published
2021
Full Text
View/download PDF

8. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

Author

Völker, Linus A., primary, Kaufeld, Jessica, additional, Balduin, Gesa, additional, Merkel, Lena, additional, Kühne, Lucas, additional, Eichenauer, Dennis A., additional, Osterholt, Thomas, additional, Hägele, Holger, additional, Kann, Martin, additional, Grundmann, Franziska, additional, Kolbrink, Benedikt, additional, Schulte, Kevin, additional, Gäckler, Anja, additional, Kribben, Andreas, additional, Boss, Kristina, additional, Potthoff, Sebastian A., additional, Rump, Lars C., additional, Schmidt, Tilman, additional, Mühlfeld, Anja S., additional, Schulmann, Karsten, additional, Hermann, Matthias, additional, Gaedeke, Jens, additional, Sauerland, Kristin, additional, Bramstedt, Jörn, additional, Hinkel, Ulrich P., additional, Miesbach, Wolfgang, additional, Bauer, Frederic, additional, Westhoff, Timm H., additional, Bruck, Heike, additional, Buxhofer-Ausch, Veronika, additional, Müller, Tobias J., additional, Wendt, Ralph, additional, Harth, Ana, additional, Schreiber, Adrian, additional, Seelow, Evelyn, additional, Tölle, Markus, additional, Gohlisch, Christopher, additional, Bieringer, Markus, additional, Geuther, Gesa, additional, Jabs, Wolfram J., additional, Fischereder, Michael, additional, Bergwelt-Baildon, Anke von, additional, Schönermarck, Ulf, additional, Knoebl, Paul, additional, Menne, Jan, additional, and Brinkkoetter, Paul T., additional

Published
2022
Full Text
View/download PDF

14. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

Author

Völker, Linus A., Kaufeld, Jessica, Balduin, Gesa, Merkel, Lena, Kühne, Lucas, Eichenauer, Dennis A., Osterholt, Thomas, Hägele, Holger, Kann, Martin, Grundmann, Franziska, Kolbrink, Benedikt, Schulte, Kevin, Gäckler, Anja, Kribben, Andreas, Boss, Kristina, Potthoff, Sebastian A., Rump, Lars C., Schmidt, Tilman, Mühlfeld, Anja S., Schulmann, Karsten, Hermann, Matthias, Gaedeke, Jens, Sauerland, Kristin, Bramstedt, Jörn, Hinkel, Ulrich P., Miesbach, Wolfgang, Bauer, Frederic, Westhoff, Timm H., Bruck, Heike, Buxhofer-Ausch, Veronika, Müller, Tobias J., Wendt, Ralph, Harth, Ana, Schreiber, Adrian, Seelow, Evelyn, Tölle, Markus, Gohlisch, Christopher, Bieringer, Markus, Geuther, Gesa, Jabs, Wolfram J., Fischereder, Michael, von Bergwelt-Baildon, Anke, Schönermarck, Ulf, Knoebl, Paul, Menne, Jan, Brinkkoetter, Paul T., Özcan, Fedai, Markau, Silke, Girndt, Matthias, Felten, Helmut, Hausberg, Martin, Brand, Marcus, Gerth, Jens, Bommer, Martin, Zschiedrich, Stefan, Schneider, Johanna, Elitok, Saban, Gawlik, Alexander, Schwenger, Vedat, Roeder, Maximilian, Radermacher, Jörg, Morgner, Anke, Herbst, Regina, and von Auer, Charis

Abstract

The von Willebrand factor–directed nanobody caplacizumab has greatly changed the treatment of immune thrombotic thrombocytopenic purpura (iTTP) in recent years. Data from randomized controlled trials established efficacy and safety.

Published
2023
Full Text
View/download PDF

18. Thr164Ile polymorphism of the human [[beta].sub.2]-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo

Author

Bruck, Heike, Leineweber, Kirsten, Ulrich, Anke, Radke, Joachim, Heusch, Gerd, Philipp, Thomas, and Broddle, Otto-Erich

Subjects
Heart beat -- Research, Biological sciences
Abstract

Bruck, Heike, Kirsten Leineweber, Anke Ulrich, Joachim Radke, Gerd Heusch, Thomas Philipp, and Otto-Erich Brodde. Thr164Ile polymorphism of the human [[beta].sub.2]-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo. Am J Physiol Heart Circ Physiol 285: H2034-H2038, 2003. First published July 17, 2003; 10.1152/ajpheart.00324.2003.--In subjects heterozygous for Thr164Ile [[beta].sub.2]-adrenoceptor ([[beta].sub.2]AR) polymorphism, cardiac responses to [[beta].sub.2]AR agonist stimulation are blunted. In this study, we investigated agonist-induced desensitization of Thr164Ile [[beta].sub.2]ARs. For this purpose, we assessed in six subjects with heterozygous Thr164Ile [[beta].sub.2.]ARs and in 10 subjects with homozygous wild-type (WT) [[beta].sub.2]ARs the effects of 2-wk oral treatment with 3 X 5 mg/day terbutaline on terbutaline infusion-induced increases in heart rate (HR) and contractility [measured as shortening of HR-corrected duration of electromechanical systole (Q[S.sub.2]c)]. Compared with WT [[beta].sub.2]AR subjects, Thr164Ile subjects exhibited a blunted terbutaline-induced maximum increase in HR (WT 32 [+ or -] 4 beats/min, Thr164Ile 19 [+ or -] 3 beats/min, P < 0.05) and contractility (WT -54 [+ or -] 2 ms, Thr164Ile -37 [+ or -] 6 ms, P < 0.05). Two-week oral terbutaline treatment desensitized cardiac [[beta].sub.2]AR responses to terbutaline infusion (increase in HR: WT 10 [+ or -] 2 beats/min, Thr164Ile 8 [+ or -] 4 beats/min; increase in contractility: WT -22 [+ or -] 5 ms Thr164Ile: -17 [+ or -] 6 ms); however, the extent of desensitization was larger in WT than Thr164Ile [[beta].sub.2]AR subjects. Thus, after 2-wk oral terbutaline treatment cardiac, [[beta].sub.2]AR responses did not differ anymore between WT and Thr164Ile [[beta].sub.2]AR subjects. We conclude that agonist-induced desensitization of cardiac [[beta].sub.2]ARs is more pronounced in WT than Thr164Ile subjects. Thus cardiac Thr164Ile subjects appear to be somewhat protected against agonist-induced desensitization. genetic polymorphism; heart rate; contractility

Published
2003

21. Caplacizumab: frequent local skin reactions

Author

Kaufeld, Jessica, primary, Brinkkoetter, Paul T., additional, Schreiber, Adrian, additional, Jabs, Wolfram J., additional, Bieringer, Markus, additional, Bruck, Heike, additional, Menne, Jan, additional, and Völker, Linus A., additional

Published
2020
Full Text
View/download PDF

32. Membranoproliferative glomerulonephritis complicating Waldenström's macroglobulinemia

Author

Kratochvil, David, Amann, Kerstin, Bruck, Heike, and Büttner, Maike

Subjects
hemic and lymphatic diseases, Medizin, cardiovascular diseases
Abstract

BACKGROUND: Lymphoproliferative disorders causing paraproteinemia can be associated with various kidney injuries including the deposition of monoclonal immunoglobulins (Ig). A known glomerular manifestation of Waldenström's macroglobulinemia is characterized by prominent intracapillary hyaline thrombi and lack of conspicuous glomerular proliferation. The present case was special in 2 aspects: 1. the diagnosis of glomerulonephritis was unexpected before renal biopsy, 2. the prominent glomerular proliferation paired with large intracapillary hyaline thrombi is uncommon in Waldenström's macroglobulinemia-associated glomerulonephritis. CASE PRESENTATION: A 73-year-old Caucasian woman with a long-standing history of rheumatoid arthritis and Waldenström's macroglobulinemia was admitted for acute renal failure (ARF), which initially was presumed to be the consequence of extrarenal causes. Proteinuria and hematuria were only mild. In renal core biopsy, a membranoproliferative glomerulonephritis (MPGN) and prominent intracapillary hyaline monoclonal IgM thrombi were found in addition to acute tubular necrosis. Of note, the patient's history was positive for purpuric skin changes, suspicious for cryoglobulinemia. However, serological tests for cryoglobulins were repeatedly negative. The ARF resolved before the start of immunomodulatory therapy for Waldenström's macroglobulinemia. CONCLUSION: The presence of MPGN with prominent hyaline thrombi in the context of Waldenström's macroglobulinemia is uncommon and can be oligosymptomatic. We discuss this case in the context of previous literature and classifications suggested for monoclonal Ig-related renal pathologies.

Published
2012

34. Factors Responsible for Plasma β-Amyloid Accumulation in Chronic Kidney Disease

Author

Gronewold, Janine, primary, Klafki, Hans-Wolfgang, additional, Baldelli, Enrico, additional, Kaltwasser, Britta, additional, Seidel, Ulla K., additional, Todica, Olga, additional, Volsek, Michaela, additional, Haußmann, Ute, additional, Wiltfang, Jens, additional, Kribben, Andreas, additional, Bruck, Heike, additional, and Hermann, Dirk M., additional

Published
2015
Full Text
View/download PDF

35. Identification of the Vasoconstriction-Inhibiting Factor (VIF), a Potent Endogenous Cofactor of Angiotensin II Acting on the Angiotensin II Type 2 Receptor

Author

Salem, Silvia, primary, Jankowski, Vera, additional, Asare, Yaw, additional, Liehn, Elisa, additional, Welker, Pia, additional, Raya-Bermudez, Ana, additional, Pineda-Martos, Carmen, additional, Rodriguez, Mariano, additional, Muñoz-Castañeda, Juan Rafael, additional, Bruck, Heike, additional, Marx, Nikolaus, additional, Machado, Fernanda B., additional, Staudt, Mareike, additional, Heinze, Georg, additional, Zidek, Walter, additional, and Jankowski, Joachim, additional

Published
2015
Full Text
View/download PDF

38. Association of Plasma β-Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease.

Author

Gronewold, Janine, Todica, Olga, Klafki, Hans-Wolfgang, Seidel, Ulla, Kaltwasser, Britta, Wiltfang, Jens, Kribben, Andreas, Bruck, Heike, and Hermann, Dirk

Abstract

Decreased β-amyloid (Aβ) clearance from the brain has been suggested to contribute to cerebral Aβ accumulation in Alzheimer's disease. Based on the idea of a dynamic Aβ equilibrium in different body compartments, plasma Aβ levels have been investigated as biomarker candidates for preclinical Alzheimer's pathology, yet with inconsistent results. Since the kidneys are involved in Aβ elimination from the blood, we evaluated how chronic kidney disease (CKD) affects the association between plasma Aβ and cognitive deficits and cognitive decline. In 28 CKD patients, stages 3-5D, and 26 control subjects with comparable vascular risk profile from the New Tools for the Prevention of Cardiovascular Disease in Chronic Kidney Disease (NT) cohort, plasma total Aβ was determined with a highly sensitive electrochemiluminescence immunoassay. Cognition was evaluated using a comprehensive battery of ten neuropsychological tests at baseline and 2-year follow-up. Subjects with high plasma Aβ level (above median) demonstrated a significantly worse baseline cognitive performance than subjects exhibiting low Aβ level (summary score of global cognitive performance at baseline z = −0.46 ± 0.76 vs z = −0.08 ± 0.57, p = 0.045). Cognitive performance moderately decreased over the 2-year follow-up in subjects with high plasma Aβ level (Δ z = −0.13 ± 0.51), but increased in subjects with low plasma Aβ level (Δ z = 0.16 ± 0.41, p = 0.023). In linear regression analyses, baseline plasma Aβ was significantly associated with cognitive decline both in unadjusted analyses ( β = −0.28, 95% CI = −0.55 to −0.01) and analyses adjusted for age ( β = −0.27, 95% CI = −0.54 to −0.01). Our results suggest the utility of plasma Aβ level in predicting cognitive decline in patients suffering from CKD. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

40. The Authors Reply

Author

Seidel, Ulla K., primary, Gronewold, Janine, additional, Kribben, Andreas, additional, Bruck, Heike, additional, and Hermann, Dirk M., additional

Published
2014
Full Text
View/download PDF

42. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, Esler, Murray D., Krum, Henry, Sobotka, Paul A., Schlaich, Markus P., Schmieder, Roland E., Böhm, Michael, Mahfoud, Felix, Sievert, Horst, Wunderlich, Nina, Rump, Lars Christian, Vonend, Oliver, Uder, Michael, Lobo, Mel, Caulfield, Mark, Erglis, Andrejs, Azizi, Michel, Sapoval, Marc, Thambar, Suku, Persu, Alexandre, Renkin, Jean, Schunkert, Heribert, Weil, Joachim, Hoppe, Uta C., Walton, Tony, Scheinert, Dierk, Binder, Thomas, Januszewicz, Andrzej, Witkowski, Adam, Ruilope, Luis M., Whitbourn, Robert, Bruck, Heike, Downes, Mark, Lüscher, Thomas F., Jardine, Alan G., Webster, Mark W., Zeller, Thomas, Sadowski, Jerzy, Bartus, Krzysztof, Straley, Craig A., Barman, Neil C., Lee, David P., Witteles, Ronald M., Bhalla, Vivek, Massaro, Joseph M., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, Esler, Murray D., Krum, Henry, Sobotka, Paul A., Schlaich, Markus P., Schmieder, Roland E., Böhm, Michael, Mahfoud, Felix, Sievert, Horst, Wunderlich, Nina, Rump, Lars Christian, Vonend, Oliver, Uder, Michael, Lobo, Mel, Caulfield, Mark, Erglis, Andrejs, Azizi, Michel, Sapoval, Marc, Thambar, Suku, Persu, Alexandre, Renkin, Jean, Schunkert, Heribert, Weil, Joachim, Hoppe, Uta C., Walton, Tony, Scheinert, Dierk, Binder, Thomas, Januszewicz, Andrzej, Witkowski, Adam, Ruilope, Luis M., Whitbourn, Robert, Bruck, Heike, Downes, Mark, Lüscher, Thomas F., Jardine, Alan G., Webster, Mark W., Zeller, Thomas, Sadowski, Jerzy, Bartus, Krzysztof, Straley, Craig A., Barman, Neil C., Lee, David P., Witteles, Ronald M., Bhalla, Vivek, and Massaro, Joseph M.

Abstract

Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (≥150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov, number NCT00888433. 106 (56) of 190 patients screened for eligibility were randomly allocated to renal denervation (n=52) or control (n=54) groups between June 9, 2009, and Jan 15, 2010. 49 (94) of 52 patients who underwent renal denervation and 51 (94) of 54 controls were assessed for the primary endpoint at 6 months. Office-based blood pressure measurements in the renal denervation group reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p<0·0001), whereas they did not differ from baseline in the control group (change of 1/0 mm Hg [21/10], baseline of 178/97 mm Hg, p=0·77 systolic and p=0·83 diastolic). Between-group differences in blood pressure at 6 months were 33/11 mm Hg (p<0·0001). At 6 months, 41 (84) of 49 patients who underwent renal denervation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 18 (35) of 51 controls (p<0·0001). We noted no serious procedure-related or device-related complications and occurrence of adver

Published
2010

43. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

Author

Esler, Murray D., Krum, Henry, Sobotka, Paul A., Schlaich, Markus P., Schmieder, Roland E., Boehm, Michael, Mahfoud, Felix, Sievert, Horst, Wunderlich, Nina, Rump, Lars Christian, Vonend, Oliver, Uder, Michael, Lobo, Mel, Caulfield, Mark, Erglis, Andrejs, Azizi, Michel, Sapoval, Marc, Thambar, Suku, Persu, Alexandre, Renkin, Jean, Schunkert, Heribert, Weil, Joachim, Hoppe, Uta C., Walton, Tony, Scheinert, Dierk, Binder, Thomas, Januszewicz, Andrzej, Witkowski, Adam, Ruilope, Luis M., Whitbourn, Robert, Bruck, Heike, Downes, Mark, Luescher, Thomas F., Jardine, Alan G., Webster, Mark W., Zeller, Thomas, Sadowski, Jerzy, Bartus, Krzysztof, Straley, Craig A., Barman, Neil C., Lee, David P., Witteles, Ronald M., Bhalla, Vivek, Massaro, Joseph M., Esler, Murray D., Krum, Henry, Sobotka, Paul A., Schlaich, Markus P., Schmieder, Roland E., Boehm, Michael, Mahfoud, Felix, Sievert, Horst, Wunderlich, Nina, Rump, Lars Christian, Vonend, Oliver, Uder, Michael, Lobo, Mel, Caulfield, Mark, Erglis, Andrejs, Azizi, Michel, Sapoval, Marc, Thambar, Suku, Persu, Alexandre, Renkin, Jean, Schunkert, Heribert, Weil, Joachim, Hoppe, Uta C., Walton, Tony, Scheinert, Dierk, Binder, Thomas, Januszewicz, Andrzej, Witkowski, Adam, Ruilope, Luis M., Whitbourn, Robert, Bruck, Heike, Downes, Mark, Luescher, Thomas F., Jardine, Alan G., Webster, Mark W., Zeller, Thomas, Sadowski, Jerzy, Bartus, Krzysztof, Straley, Craig A., Barman, Neil C., Lee, David P., Witteles, Ronald M., Bhalla, Vivek, and Massaro, Joseph M.

Abstract

Background Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. Methods In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (>= 150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov, number NCT00888433. Findings 106 (56%) of 190 patients screened for eligibility were randomly allocated to renal denervation (n=52) or control (n=54) groups between June 9, 2009, and Jan 15, 2010. 49 (94%) of 52 patients who underwent renal denervation and 51 (94%) of 54 controls were assessed for the primary endpoint at 6 months. Office-based blood pressure measurements in the renal denervation group reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p<0.0001), whereas they did not differ from baseline in the control group (change of 1/0 mm Hg [21/10], baseline of 178/97 mm Hg, p=0.77 systolic and p=0.83 diastolic). Between-group differences in blood pressure at 6 months were 33/11 mm Hg (p<0.0001). At 6 months, 41 (84%) of 49 patients who underwent renal denervation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 18 (35%) of 51 controls (p<0.0001). We noted no serious procedure-related or device-related complicatio

Published
2010

46. Relationship between Magnesium and Clinical Biomarkers on Inhibition of Vascular Calcification

Author

Salem, Silvia, primary, Bruck, Heike, additional, Bahlmann, Ferdinand H., additional, Peter, Mirjam, additional, Passlick-Deetjen, Jutta, additional, Kretschmer, Axel, additional, Steppan, Sonja, additional, Volsek, Michaela, additional, Kribben, Andreas, additional, Nierhaus, Marc, additional, Jankowski, Vera, additional, Zidek, Walter, additional, and Jankowski, Joachim, additional

Published
2011
Full Text
View/download PDF

49. Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Author

Halabi, Atef, primary, Maatouk, Haidar, additional, Klause, Norbert, additional, Lufft, Volkmar, additional, Kubitza, Dagmar, additional, Zuehlsdorf, Michael, additional, Becka, Michael, additional, Mueck, Wolfgang, additional, Schäfers, Rafael, additional, Wand, Dominic, additional, Philipp, Thomas, additional, and Bruck, Heike, additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results